Please upgrade your browser.
We report a 13-year-old white girl with epilepsy and hypopigmented skin lesions...
Life experience doesn't prepare you for cancer caregiving.
Genetics can sometimes explain why some people respond well to a drug whereas others may experience serious side effects. The InVite Study is a collaborative effort between 23andMe and Genentech to learn more about how genes influence response to bevacizumab (also known as Avastin®) in the treatment of locally recurrent or metastatic breast cancer, metastatic colorectal cancer, metastatic non-squamous non-small cell lung cancer, recurrent glioblastoma, or metastatic renal cell carcinoma.
Cancer is a leading cause of death worldwide. In 2008, it was the cause of 7.6 million deaths globally, and it is estimated that a third of those deaths could have been avoidable with greater prevention, early detection and existing treatments.
Shrive was one of seven finalists this year and becomes the fifth recipient of the award.
David participated in a Phase 2 clinical study that evaluated a personalized cancer immunotherapy in combination with a standard targeted drug therapy, sunitinib.
Emails Tell the Story of the NCI Cancer Bulletin
SAN ANTONIO - Five years, local attorney Henry Grun had his will ready to be executed at the request of his first oncologist, who warned him that his kidney cancer was so aggressive he had only six months to live.
Astellas Pharma today announced that new clinical data on tivozanib, an investigational agent for the treatment of metastatic renal cell carcinoma (mRCC), will be presented at the 2013 American society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 14-16 in Orlando, Florida.
|Powered by NeonCRM|